Literature DB >> 25420938

MicroRNA-155 promotes the proliferation and invasion abilities of colon cancer cells by targeting quaking.

Bin He1, Sheng-Qiang Gao1, Li-Dong Huang1, Yue-Han Huang1, Qi-Yu Zhang1, Meng-Tao Zhou1, Hong-Qi Shi1, Qi-Tong Song1, Yun-Feng Shan1.   

Abstract

The increasing expression of microRNA‑155 (miR‑155) and decreasing expression of RNA‑binding protein quaking (QKI) in colon cells have been observed previously. In this study, we attempted to establish the correlation between miR‑155 and QKI. In addition, we assessed whether the expression of miR‑155 and QKI is linked to the proliferation and invasion capabilities of colon cells. Firstly, nineteen tumor samples, divided into two groups according to the presence or absence of lymphatic metastasis, were obtained from colon cancer patients at the First Affiliated Hospital of Wenzhou Medical University, China. The expression level of miR‑155 and QKI was measured by quantitative polymerase chain reaction (qPCR). Secondly, the GES‑1, SW480 and COLO205 cell lines were cultured and the expression level of QKI and miR‑155 was also assessed by qPCR. Thirdly, a luciferase reporter gene assay was performed to detect the association between miR‑155 and QKI, and qPCR and western blot analysis were performed to confirm the effects of miR‑155 on the expression of QKI at the mRNA and protein level. Subsequently, the SW480 cells were used in the following experiments. Following treatment with miR‑155 inhibitor and QKI overexpression vector, western blot analysis, propidium iodide (PI) staining and a cell scratch assay were carried out to assess the effects of miR‑155 on the proliferation and invasion potential of colon cancer cells. qPCR findings revealed higher miR‑155 expression and lower QKI expression in colon cancer tissues as well as the colon cancer cell lines SW480 and COLO205. The relative luciferase activity of the 3' untranslated region (3'UTR) was decreased by approximately 45% when SW480 cells stimulated by mimic‑miR‑155 were combined with the wild‑type 3'UTR constructs. In addition, when the cells were treated with mimic‑miR‑155, QKI expression was significantly decreased at the mRNA and protein level. These outcomes revealed that miR‑155 decreased the production of QKI by acting on the 3'UTR of the QKI gene. Furthermore, PI staining and the cell scratch assay revealed that miR‑155 influenced the cell cycle and invasion abilities of colon cancer cells by directly targeting QKI and decreased the production of QKI by acting on the 3'UTR of the QKI gene. This study has demonstrated the correlation between miR‑155 and QKI, in which miR‑155 regulates the cell cycle and invasion ability of colon cancer cells via the modulation of QKI expression. Our study provides novel therapeutic strategies for colon cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25420938     DOI: 10.3892/mmr.2014.2994

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  17 in total

1.  Epigenetic Regulation of Metabolism and Inflammation by Calorie Restriction.

Authors:  Diego Hernández-Saavedra; Laura Moody; Guanying Bianca Xu; Hong Chen; Yuan-Xiang Pan
Journal:  Adv Nutr       Date:  2019-05-01       Impact factor: 8.701

2.  MicroRNA-21 and microRNA-155 promote the progression of Burkitt's lymphoma by the PI3K/AKT signaling pathway.

Authors:  Bo Han; Shuguo Wang; Hongguo Zhao
Journal:  Int J Clin Exp Pathol       Date:  2020-01-01

3.  A large-scale analysis of alternative splicing reveals a key role of QKI in lung cancer.

Authors:  Fernando J de Miguel; María J Pajares; Elena Martínez-Terroba; Daniel Ajona; Xabier Morales; Ravi D Sharma; Francisco J Pardo; Ana Rouzaut; Angel Rubio; Luis M Montuenga; Ruben Pio
Journal:  Mol Oncol       Date:  2016-08-09       Impact factor: 6.603

4.  MicroRNA-155 deletion promotes tumorigenesis in the azoxymethane-dextran sulfate sodium model of colon cancer.

Authors:  Kandy T Velázquez; Reilly T Enos; Jamie L McClellan; Taryn L Cranford; Ioulia Chatzistamou; Udai P Singh; Mitzi Nagarkatti; Prakash S Nagarkatti; Daping Fan; E Angela Murphy
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-01-07       Impact factor: 4.052

Review 5.  MicroRNAs as biomarkers and prospective therapeutic targets in colon and pancreatic cancers.

Authors:  Ganji Purnachandra Nagaraju; Appiya Santharam Madanraj; Sheik Aliya; Balney Rajitha; Olatunji Boladale Alese; Ekamber Kariali; Afroz Alam; Bassel F El-Rayes
Journal:  Tumour Biol       Date:  2015-11-04

6.  Anti-miR delivery strategies to bypass the blood-brain barrier in glioblastoma therapy.

Authors:  Dong Geon Kim; Kang Ho Kim; Yun Jee Seo; Heekyoung Yang; Eric G Marcusson; Eunju Son; Kyoungmin Lee; Jason K Sa; Hye Won Lee; Do-Hyun Nam
Journal:  Oncotarget       Date:  2016-05-17

7.  MiR-143-3p functions as a tumor suppressor by regulating cell proliferation, invasion and epithelial-mesenchymal transition by targeting QKI-5 in esophageal squamous cell carcinoma.

Authors:  Zhenyue He; Jun Yi; Xiaolong Liu; Jing Chen; Siqi Han; Li Jin; Longbang Chen; Haizhu Song
Journal:  Mol Cancer       Date:  2016-06-29       Impact factor: 41.444

8.  MicroRNA-155 acts as a tumor suppressor in colorectal cancer by targeting CTHRC1 in vitro.

Authors:  Jingtian Liu; Zongyou Chen; Jianbin Xiang; Xiaodong Gu
Journal:  Oncol Lett       Date:  2018-02-16       Impact factor: 2.967

9.  The miR-17-92 cluster/QKI2/β-catenin axis promotes osteosarcoma progression.

Authors:  Hongbo Yang; Zhibin Peng; Min Liang; Yubo Zhang; Yangyang Wang; Tianwen Huang; Yudong Jiang; Bo Jiang; Yansong Wang
Journal:  Oncotarget       Date:  2018-01-05

10.  Andrographolide enhances the anti-metastatic effect of radiation in Ras-transformed cells via suppression of ERK-mediated MMP-2 activity.

Authors:  Chih-Chia Yu; Chien-An Chen; Shu-Ling Fu; Hon-Yi Lin; Moon-Sing Lee; Wen-Yen Chiou; Yu-Chieh Su; Shih-Kai Hung
Journal:  PLoS One       Date:  2018-10-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.